Coronavirus vaccine: Good news on AstraZeneca/Oxford antidote

The British pharmaceutical company AstraZeneca announced on Monday, October 26, good news on the progress of its coronavirus vaccine (Covid-19).

According to the British daily newspaper Financial Times, AstraZeneca "s vaccine, which is currently in phase 3, produced an encouraging immune response in the patients tested.

"An AstraZeneca spokesman working on the vaccine with Oxford University points out that these immune responses are similar between older people and young adults," the same source said, pointing out that "the results add to the evidence about the safety and immune response of the vaccine.

AstraZeneca's vaccine, developed by Oxford University, is currently in the larger Phase 3 clinical trials, the stage prior to regulatory approval.